Ralph Raymond Minter

USPTO Granted Patents = 31 (Patent Applications = 19)

CIPO Patents = 6 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 7.6

ph-index = 6

Forward Citations = 116(Granted Patents)

Location History:

London, GB (2011 - 2013)
Granta Park, GB (2011 - 2015)
Cambrdige, GB (2016)
Cambirdge, GB (2018)
Cambridge, GB (2008 - 2022)

Company Filing History:

Agouron Pharmaceuticals, Inc.

patents

4. 2 out of 10

Zenyth Operations Pty. Ltd.

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12428473 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2025-09-30),

2. 11525012 - Binding molecules specific for CD73 and uses thereof (2022-12-13),

3. 11203633 - Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv (2021-12-21),

4. 11192948 - Compositions and methods for inhibiting cancer stem cells (2021-12-07),

5. 10844114 - Anti-Psl binding molecules and uses thereof (2020-11-24),

6. 10597439 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2020-03-24),

7. 10556968 - Binding molecules specific for CD73 and uses thereof (2020-02-11),

8. 10370436 - Anti-pseudomonas Psl binding molecules and uses thereof (2019-08-06),

9. 10329345 - Stabilized angiopoietin-2 antibodies and uses thereof (2019-06-25),

10. 10287362 - Binding molecules specific for CD73 and uses thereof (2019-05-14),

11. 9938356 - Binding molecules specific for CD73 and uses thereof (2018-04-10),

12. 9884902 - CTLA-4 variants (2018-02-06),

13. 9856317 - Human antibody molecules for IL-13 (2018-01-02),

14. 9580509 - Multispecific and multivalent binding proteins and uses thereof (2017-02-28),

15. 9403901 - Anti-pseudomonas Psl binding molecules and uses thereof (2016-08-02),

Title: Ralph Raymond Minter: Innovator in Antibody Development

Introduction: Ralph Raymond Minter, based in London, GB, is a prominent inventor known for his groundbreaking work in the field of medicine, particularly in the development of antibodies and therapeutic applications. With an impressive portfolio of 30 patents, Minter has made significant contributions to the understanding and treatment of diseases associated with CD73-expression, including various forms of cancer.

Latest Patents: Among his notable recent patents is the invention of binding molecules specific for CD73. This innovation provides anti-CD73 binding molecules, such as antibodies and their antigen-binding fragments, which can be utilized in pharmaceutical formulations. These compositions demonstrate promising methods for diagnosing and treating diseases where CD73 is expressed. Minter's approach includes strategies for direct therapy with these anti-CD73 molecules, adjuvant therapy in conjunction with other immune checkpoint inhibitors, and potential combination therapies alongside chemotherapy. Additionally, Minter is recognized for his work on polynucleotides encoding antibodies or antigen-binding fragments designed to bind to PcrV, expanding the arsenal of targeted therapy options against specific pathogens.

Career Highlights: Throughout his career, Ralph Minter has held critical roles in leading companies in the biotechnology sector, including MedImmune Limited and Wyeth. His work in these organizations has been instrumental in advancing therapeutic innovations and improving health outcomes.

Collaborations: Minter has collaborated with esteemed professionals such as Sandrine Guillard and Lutz Jermutus, contributing to the collective efforts in antibody research and development. These collaborations have enriched the scientific community's understanding of therapeutic antibodies.

Conclusion: Ralph Raymond Minter stands out as a key figure in the field of antibody development, with a robust portfolio of patents that reflect his innovative spirit and commitment to advancing medical science. His contributions continue to pave the way for novel treatments that address critical health challenges related to CD73 and other targets.

This text is generated by artificial intelligence and may not be accurate.